Role of CSF-1 in progression of epithelial ovarian cancer

Future Oncology

Volumn 5, Issue 9, 2009, Pages 1429-1440

  Chambers, Setsuko K ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

c fms proto oncogene; CSF 1; Epithelial ovarian cancer; HuR; Invasion; Metastasis; Post transcriptional regulation; Urokinase

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; A 6; ANTINEOPLASTIC AGENT; B 428; BRCA1 PROTEIN; BRCA2 PROTEIN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; CYT 645; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMATINIB; INTERLEUKIN 6; KI 20227; MESSENGER RNA; MICRORNA; MYC PROTEIN; PLACEBO; PROTEIN P53; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN; VATALANIB;

3' UNTRANSLATED REGION; AUTOCRINE EFFECT; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG POTENCY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; METASTASIS POTENTIAL; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; DISEASE COURSE; FEMALE; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY;

DISEASE PROGRESSION; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 74949093638     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.103     Document Type: Review

References (123)

1. Harries M, Gore M: Part I. Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3(9), 529-536 (2002).
2. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
3. Landen CN Jr, Birrer MJ, Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26(6), 995-1005 (2008).
4. Wong KK, Lu KH, Malpica A et al.: Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int. J. Gynecol. Pathol. 26(4), 404-409 (2007).
5. Callahan MJ, Crum CP, Medeiros CP et al.: Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 25, 3985-3900 (2007).
6. Jarboe EA, Folkins A, Nucci MR et al.: Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 27(1), 1-9 (2008).
7. Lee Y, Miron A, Drapkin R et al.: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211(1), 26-35 (2007).
8. Cecchini MG, Hofstetter W, Halasy J, Wetterwald A, Felix R: Role of CSF-1 in bone and bone marrow development. Mol. Reprod. Dev. 46, 75-84 (1997).
9. Pollard JW, Bartocci A, Arceci R et al.: Apparent role of the macrophage growth factor, CSF-1, in placental development. Nature 330, 484-486 (1987).
10. Cohen PE, Zhu L, Pollard JW: Absence of colony stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice disrupts estrous cycles and ovulation. Bio. Reprod. 56, 110-118 (1997).
11. Sapi E: The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp. Biol. Med. 229(1), 1-11 (2004).
12. Pollard JW, Stanley ER, Paul MW: Pleiotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic. Adv. Dev. Biochem. 4, 153-193 (1996).
13. Ryan GR, Dai XM, Dominguez MG et al.: Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1op/Csf1op) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood 98(1), 74-84 (2001).
14. Dai XM, Ryan GR, Hapel AJ et al.: Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99(1), 111-120 (2002).
15. Clouser M, Hess LM, Chambers SK: Biomarker targets and novel therapeutics. Cancer Treat. Res. 149, 85-105 (2009).
16. Stanley ER, Berg KL, Einstein DB et al.: Biology and action of colony-stimulating factor-1. Mol. Reprod. Develop. 46(1), 4-10 (1997).
17. Arceci RJ, Shanahan F, Stanley ER, Pollard JW: Temporal expression and location of colony-stimulating factor (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1 regulated placental development. Proc. Natl Acad. Sci. USA 86, 8818-8822 (1989).
18. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr et al.: Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl Acad. Sci. USA 87(12), 4828-4832 (1990).
19. Filderman AE, Bruckner A, Kacinski BM, Deng N, Remold HG: Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor positive carcinoma cell lines. Cancer Res. 52, 3661-3666 (1992).
20. Ide H, Seligson DB, Memarzadeh L et al.: Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc. Natl Acad. Sci. USA 99(22), 14404-14409 (2002).
21. Kacinski BM, Carter D, Mittal K et al.: Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am. J. Pathol. 137, 35-147 (1990).
22. Kacinski BM, Chambers SK, Stanley ER et al.: The cytokine CSF-1 (M-CSF), whose receptors are expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity for endometrial carcinoma patients. Int. J. Radiat. Oncol. Biol. Phys. 19, 619-626 (1990).
23. Kacinski BM, Scata KA, Carter D et al.: FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6, 941-952 (1991).
24. Rettenmier CW, Sacca R, Furman WL et al.: Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. J. Clin. Invest. 77, 1740-1746 (1989).
25. Chambers SK, Ivins CM, Kacinski BM, Hochberg RB: An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells expressing little glucocorticoid receptor. Am. J. Obstet. Gynecol. 190, 974-985 (2004).
26. Keshava N, Gubba S, Tekmal RR: Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis. J. Soc. Gynecol. Invest. 6(1), 41-49 (1999).
27. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML: Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin. Cancer Res. 3(6), 999-1007 (1997).
28. Maher MG, Sapi E, Turner B et al.: Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin. Cancer Res. 4, 1851-1856 (1998).
29. Price FV, Chambers SK, Chambers JT et al.: CSF-1 concentration in primary ascites of ovarian cancer is a significant predictor of survival. Am. J. Obstet. Gynecol. 68, 520-527(1993).
30. Scholl S, Bascou CH, Mosseri V et al.: Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br. J. Cancer 62, 342-346 (1994).
31. Toy EP, Chambers JT, Kacinski BM, Flick MB, Chambers SK: The activated macrophage colony stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol. Oncol. 80, 194-200 (2001).
32. Tang R, Kacinski B, Validire P et al.: Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J. Cell. Biochem. 44, 189-198 (1990).
33. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL: Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin. Cancer Res. 10(1 Pt 1), 173-177 (2004).
34. Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurzrock R: Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer 67(4), 990-996 (1991).
35. Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK: Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony stimulating factor (CSF-1). Neoplasia 11(2), 136-144 (2009).
36. Sapi E, Flick MB, Rodov S et al.: Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res. 56, 5704-5712 (1996).
37. Kacinski BM, Stanley ER, Carter D et al.: Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int. J. Radiat. Oncol. Biol. Phys. 17, 159-164 (1989).
38. Skates SJ, Horick N, Yu Y et al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-13, CA 72-74, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22, 4059-4066 (2004).
39. Zhang Z, Yu Y, Xu F et al.: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol. Oncol. 107, 526-531 (2007).
40. Flick MB, Sapi E, Perrotta PL et al.: Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody. Oncogene 14, 2553-2561 (1997).
41. Scholl SM, Mosseri V, Tang R, Pouillart P: Expression of colony stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells. Ann. NY Acad. Sci. 698, 131-135 (1993).
42. Wrobel CN, Debnath J, Lin E, Beausoleil S, Roussel MF, Brugge JS: Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture. J. Cell Biol. 165(2), 263-273 (2004).
43. Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193(6), 727-740 (2001).
44. Toy EP, Bonafe N, Savlu A et al.: Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. Clin. Exp. Metast. 22(1), 1-9 (2005).
45. Tamimi RM, Brugge JS, Freedman ML et al.: Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res. 68(1), 18-21 (2008).
46. Scholl SM, Pallud C, Beuvon F et al.: Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl Cancer Inst. 86, 120-126 (1994).
47. Bonafe N, Gilmore-Hebert M, Folk NL, Azodi M, Zhou Y, Chambers SK: Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-rich 3′ UTR of CSF-1 mRNA in human ovarian cancer cells: possible role in CSF-1 post-transcriptional regulation and tumor phenotype. Cancer Res. 65(9), 3762-3771 (2005).
48. Chambers SK, Wang Y, Gertz RE, Kacinski BM: Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res. 55(7), 1578-1585 (1995).
49. Woo HH, Zhou Y, Yi X et al.: Regulation of non AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene 28(9), 1176-1189 (2009)
50. Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG: Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res. 52, 3043-3047 (1992).
51. Hamilton JA, Whitty GA, Stanton H, Meager A: Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-α. J. Leuk. Biol. 53, 707-714 (1993).
52. Kuhn W, Schmalfeldt B, Reuning U et al.: Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer 79(11-12), 1746-1751 (1999).
53. van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG, Foekens JA: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer 69(6), 475-479 (1996).
54. Saldanha RG, Molloy MP, Bdeir K et al.: Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J. Proteome Res. 6(3), 1016-1028 (2007).
55. Chambers SK, Ivins CM, Carcangiu ML: Urokinase-type plasminogen activator in epithelial ovarian cancer: a poor prognostic factor, associated with advanced stage. Int. J. Gynecol. Cancer 8, 242-250 (1998).
56. Chambers SK, Ivins CM, Carcangiu ML: Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int. J. Cancer 79, 449-454 (1998).
57. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metast. 13, 296-302 (1995).
58. Towle MJ, Lee A, Maduakor EC et al.: Inhibition of urokinase by 4-substituted Benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. 53, 2553-2559 (1993).
59. Nowicki A, Szenajch J, Ostrowska G et al.: Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer 65(1), 112-119 (1996).
60. Aharinejad S, Abraham D, Paulus P et al.: Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res. 62(18), 5317-5324 (2002).
61. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64, 5378-5384 (2004).
62. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 66(8), 4349-4356 (2006).
63. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78 (2004).
64. Hagemann T, Wilson J, Burke F et al.: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 176(8), 5023-5032 (2006).
65. Hagemann T, Wilson J, Kulbe H et al.: Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J. Immunol. 175(2), 1197-1205 (2005).
66. Hidaka T, Akada S, Teranishi A et al.: Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function. Cancer Sci. 94(9), 814-820 (2003).
67. Mizutani K, Takeuchi S, Ohashi Y et al.: Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: long-term prognosis after five years. Oncol. Rep. 10(1), 127-131 (2003).
68. Chambers SK, Gilmore-Hebert M, Wang Y, Rodov S, Benz EJ, Kacinski BM: Post-transcriptional regulation of CSF-1 and CSF-1 receptor gene expression during inhibition of phorbol-ester induced monocytic differentiation by dexamethasone and cyclosporin A: potential involvement of a destabilizing protein. Exp. Hematol. 21, 1328-1334 (1993).
69. de Wit H, Esselink MT, Halie MR, Ballenga E: Differential regulation of M-CSF and IL-6 expression in monocytic cells. Br. J. Haematol. 86, 259-264 (1994).
70. Ernst TJ, Ritchie AR, Demetri GD, Griffin JD: Regulation of granulocyte-and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J. Biol. Chem. 264, 5700-5703 (1989).
71. Horiguchi J, Sariban E, Kufe D: Transcriptional and posttranscriptional regulation of CSF-1 gene expression in human monocytes. Mol. Cell. Biol. 8, 3951-3954 (1988).
72. Sherman ML, Weber BL, Datta R, Kufe DW: Transcriptional and posttranscriptional regulation of macrophage-specific colony stimulating factor gene expression by tumor necrosis factor. J. Clin. Invest. 85, 442-447 (1990).
73. Suen Y, Lee SM, Schreurs J, Knoppel E, Cairo MS: Decreased macrophage colony-stimulating factor mRNA expression from activated cord versus adult mononuclear cells: altered posttranscriptional stability. Blood 84, 4269-4277 (1994).
74. Borycki A, Lenormund J, Guillier M, Leibovitch SA: Isolation and characterization of a cDNA clone encoding for rat CSF-1 gene. Post-transcriptional repression occurs in myogenic differentiation. Biochim. Biophys. Acta 1174, 143-152 (1993).
75. Falkenburg JHF, Harrington MA, de Paus RA et al.: Differential transcriptional and postranscriptional regulation of gene expression of the colony-stimulating factors by interleukin-1 and fetal bovine serum in murine fibroblasts. Blood 78, 658-665 (1991).
76. Rubin J, Fan D, Wade A et al.: Transcriptional regulation of the expression of macrophage colony stimulating factor. Mol. Cell Endocrinol. 160, 193-202 (2000).
77. Cheadle C, Fan J, Cho-Chung YS et al.: Stability regulation of mRNA and the control of gene expression. Ann. NY Acad. Sci. 1058, 196-204 (2005).
78. Colegrove-Otero LJ, Minshall N, Standart N: RNA-binding proteins in early development. Crit. Rev. Biochem. Mol. Biol. 40, 21-73 (2005).
79. Bassell GJ, Kelic S: Binding proteins for mRNA localization and local translation, and their dysfunction in genetic neurological disease. Curr. Opin. Neurobiol. 14, 574-578 (2004).
80. Musunuru K: Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc. Med. 13, 188-195 (2003).
81. Gouble A, Grazide S, Meggetto F, Mercier P, Delsol G, Morello D: A new player in oncogenesis: AUF1/hnRNPD over-expression leads to tumorigenesis in transgenic mice. Cancer Res. 62, 1489-1495 (2002).
82. Tessier CR, Doyle GA, Clark BA, Pitot HC, Ross J: Mammary tumor induction in transgenic mice expressing an RNA-binding protein. Cancer Res. 64, 209-214 (2004).
83. Stoecklin G, Gross B, Ming X-F, Moroni C: A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 22(23), 3554-3561 (2003).
84. Sachs AB: Messenger RNA degradation in eukaryotes. Cell 74, 413-421 (1993).
85. Xie X, Lu J, Kulbokas EJ et al.: Systematic discovery of regulatory motifs in human promoters and 3′UTRs by comparison of several mammals. Nature 434(7031), 338-345 (2005).
86. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo Y-Y: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18, 350-359 (2008).
87. Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163), 682-688 (2007).
88. Tavazoie SF, Alarcon C, Oskarsson T et al.: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008).
89. Mitchell PS, Parkin RK, Kroh EM et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
90. Sorrentino A, Lui CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111(3), 478-486 (2008).
91. Chambers SK, Kacinski BM: Messenger RNA decay of macrophage colony-stimulating factor in human ovarian carcinomas in vitro. J. Soc. Gynecol. Investig. 1, 310-316 (1994).
92. Price LKH, Choi HU, Rosenberg L, Stanley ER: The predominant form of secreted colony stimulating factor-1 is a proteoglycan. J. Biol. Chem. 267, 2190-2199 (1992).
93. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr, Brown EL: Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J. Clin. Invest. 83(3), 921-926, (1989).
94. Shaw G, Kamen R: A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667 (1986).
95. Wong GG, Temple PA, Leary AC et al.: Human CSF-1: molecular cloning and expression of 4-kb cDNA encoding the human urinary protein. Science 235, 1504-1508 (1987).
96. Vasudevan S, Steitz JA: AU-rich-element-mediated upregulation of translation by FXR1 and argonaute 2. Cell 128(6), 1105-1118 (2007).
97. Fan H, Villegas C, Huang A, Wright JA: Suppression of malignancy by the 3′ untranslated regions of ribonucleotide reductase R1 and R2 messsenger RNAs. Cancer Res. 56, 4366-4369 (1996).
98. Meijlink F, Curran T, Miller AD, Verma IM: Removal of a 67-base-pair sequence in the noncoding region of proto-oncogene c-fos converts it to a transforming gene. Proc. Natl Acad. Sci. USA 82, 4987-4991 (1985).
99. Rastinejad F, Conboy MJ, Rando TA, Blau HM: Tumor suppression by RNA from the 3′ untranslated region of α-tropomyosin. Cell 75, 1107-1117 (1993).
100. Wodnar FA, Moroni C: Regulation of interleukin 3 mRNA expression in mast cells occurs at the posttranscriptional level and is mediated by calcium ions. Proc. Natl Acad. Sci. USA 87, 777-781 (1990).
101. Rastinejad F, Blau HM: Genetic complementation reveals a novel regulatory role for 3′ untranslated regions in growth and differentiation. Cell 72, 903-917 (1993).
102. Zhou Y, Yi X, Stoffer JB et al.: The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls CSF-1 mRNA stability in ovarian cancer. Mol. Cancer Res. 6(8), 1375-1384 (2008).
103. Sirover MA: New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J. Cell Biochem. 95, 45-52 (2005).
104. Xie Y, Chen C, Hume DA: Transcriptional regulation of c-fms gene expression. Cell Biochem. Biophys. 34, 1-16 (2001).
105. Weber B, Horiguchi J, Luebbers R, Sherman M, Kufe D: Posttranscriptional stabilization of c-fms mRNA by a labile protein during human monocytic differentiation. Mol. Cell Biol. 9, 769-775 (1989).
106. Stone RM, Imamura K, Datta R, Sherman ML, Kufe DW: Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites. Blood 76, 1225-1232 (1990).
107. Sapi E, Flick MB, Gilmore-Hebert M, Rodov S, Kacinski BM: Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene 10, 529-542 (1995).
108. Kacinski BM, Flick MB, Sapi E: RU-486 can abolish glucocorticoid-induced increases in CSF-1 receptor expression in primary human breast carcinoma specimens. J. Soc. Gynecol. Investig. 8, 114-116 (2001).
109. Flick MB, Sapi E, Kacinski BM: Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element. J. Cell Biochem. 85, 10-23 (2002).
110. Chambers SK, Wang Y, Gilmore-Hebert M, Kacinski BM: Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro. Steroids 59, 514-522 (1994).
111. Brennan CM, Steitz JA: HuR and mRNA stability. Cell. Mol. Life Sci. 58(2), 266-277 (2001).
112. Mazan-Mamczarz K, Hagner PR, Corl S et al.: Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 27(47), 6151-6163 (2008).
113. Denkert C, Weichert W, Pest S et al.: Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res. 64, 189-195 (2004).
114. Erkinheimo TL, Lassus H, Sivula A et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 63(22), 7591-7594 (2003).
115. Heinonen M, Bono P, Narko K et al.: Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 65, 2157-2161 (2005).
116. Lopez de Silanes I, Fan J, Yang X et al.: Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 22(46), 7146-7154 (2003).
117. Nabors LB, Gillespie GY, Harkins L, King PH: HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 61(5), 2154-2161 (2001)
118. Yi X, Zhou Y, Zheng W, Chambers SK: HuR expression in the nucleus correlates with high histologic grade and poor disease-free survival in ovarian cancer. Aust. NZ J. Obstet. Gynaecol. 49(1), 93-98 (2009).
119. Alberts DS, Liu PY, Wilczynski SP et al.: Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int. J. Gynecol. Cancer 17(4), 784-788 (2007).
120. Kluger HM, Kluger Y Gilmore-Hebert M et al.: cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab. Investig. 84, 320-331 (2004).
121. Hussain MM, Kotz H, Minasian L et al.: Phase II trial of carboxyamidotriazole inpatients with relapsed epithelial ovarian cancer. J. Clin. Oncol. 21(23), 4356-4363 (2003).
122. Berkenblit A, Matulonis UA, Kroener JF et al.: A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a Phase I trial. Gynecol. Oncol. 99(1), 50-57 (2005).
123. Ghamande SA, Silverman MH, Huh W et al.: A Phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol. 111(1), 89-94 (2008).